Evaluation in Nonhuman Primates of Vaccines against Ebola Virus

Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EB...

Full description

Bibliographic Details
Main Authors:	Geisbert, Thomas W., Pushko, Peter, Anderson, Kevin, Smith, Jonathan, Davis, Kelly J., Jahrling, Peter B.
Format:	Online
Language:	English
Published:	Centers for Disease Control and Prevention 2002
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369765/

id	pubmed-3369765
recordtype	oai_dc
spelling	pubmed-33697652012-06-19 Evaluation in Nonhuman Primates of Vaccines against Ebola Virus Geisbert, Thomas W. Pushko, Peter Anderson, Kevin Smith, Jonathan Davis, Kelly J. Jahrling, Peter B. Perspective Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms. Centers for Disease Control and Prevention 2002-05 /pmc/articles/PMC3369765/ /pubmed/11996686 http://dx.doi.org/10.3201/eid0805.010284 Text en
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Geisbert, Thomas W. Pushko, Peter Anderson, Kevin Smith, Jonathan Davis, Kelly J. Jahrling, Peter B.
spellingShingle	Geisbert, Thomas W. Pushko, Peter Anderson, Kevin Smith, Jonathan Davis, Kelly J. Jahrling, Peter B. Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
author_facet	Geisbert, Thomas W. Pushko, Peter Anderson, Kevin Smith, Jonathan Davis, Kelly J. Jahrling, Peter B.
author_sort	Geisbert, Thomas W.
title	Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
title_short	Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
title_full	Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
title_fullStr	Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
title_full_unstemmed	Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
title_sort	evaluation in nonhuman primates of vaccines against ebola virus
description	Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.
publisher	Centers for Disease Control and Prevention
publishDate	2002
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369765/
_version_	1611535277010976768

Evaluation in Nonhuman Primates of Vaccines against Ebola Virus

Similar Items